z-logo
open-access-imgOpen Access
Ingenol Mebutate 500 µg on the Cheekbones with Concomitant Conjunctivitis
Author(s) -
Olivier Gaide,
Vincent Cattin
Publication year - 2016
Publication title -
dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.224
H-Index - 92
eISSN - 1421-9832
pISSN - 1018-8665
DOI - 10.1159/000447387
Subject(s) - medicine , dermatology , erythema , actinic keratosis , concomitant , regimen , surgery , basal cell
Ingenol mebutate induces strong inflammation after a single application already. This must be taken into account when prescribing the drug, as mistakes in the application may results in severe side effects. Here, we report the case of a 72-year-old woman who applied ingenol mebutate on the cheekbones and developed a pronounced conjunctivitis, needing topical corticosteroids. The treatment was intended for the actinic keratosis she had on the chest, and the regimen of 2 consecutive once daily applications of ingenol mebutate at 500 µg/g had been prescribed as registered. The inadvertent application on the thin skin of the cheekbones led to a pronounced inflammation. With topical steroids followed by fusidic acid, both conjunctivitis and skin inflammation resolved within a few days. The skin showed erythema for a few weeks, but after 3 months, the patient presented a perfectly smooth skin and was very happy with the cosmetic outcome. This suggests that the cheekbones are a sensitive site for ingenol mebutate, but that intense inflammation should not scare physician or patient, as clinical remission with excellent healing can still be expected.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here